Two of the women behind NeuroSense Therapeutics share their life stories and discuss the special value of women in the scientific world.


Read about the promising preliminary results of our clinical trial in ALS patients.


NeuroSense kicks off two clinical trials in three sites in the US and Israel, and receives orphan drug designation from the FDA, for the treatment of ALS with PrimeC.


Ariel Gordon and Yossi Gross, two of our investors, talk about the reasons that led them to play an active role in developing a cure for ALS.


NeuroSense Therapeutics CEO, Alon Ben-Noon, discusses ALS, our drug PrimeC, and the novel ALS zebrafish model.


The amazing story about how Dr. Niva Russek-Blum, the scientist who spent years screening hundreds of potential drugs for ALS, to no avail, finally found a high-efficacy combination drug in collaboration with NeuroSense Therapeutics.